Skip to content
2000
Volume 17, Issue 8
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Selective inhibition of cyclooxygenase-2 (COX-2) isozyme afforded a useful drug design concept that resulted in the development of effective anti-inflammatory drugs that are devoid of adverse side effects, in particular gastrointestinal irritation, ulcerogenicity and renal toxicity attributed to inhibition of the cytoprotective cyclooxygenase-1 (COX-1) isozyme. Unfortunately, some selective COX-2 inhibitory drugs such as rofecoxib and valdecoxib are believed to be responsible for cardiovascular complications. Nitric oxide (NO) is an effective vasodilator that also inhibits platelet aggregation. Therefore hybrid NSAIDs containing NO-donor moieties have been developed to obtain effective treatment of inflammation with reduced GI and cardiovascular side effects. Here we review some of the most promising recent advances in NO-NAISDs donor drug development and summarizes medicinal chemistry efforts in search for new NO-NSAIDs prodrugs in an attempt to pave the way for further development in this promising area of research.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026616666160927153435
2017-03-01
2025-07-04
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026616666160927153435
Loading

  • Article Type:
    Research Article
Keyword(s): Anti-inflammatory agents; Cyclooxygenase inhibition; Nitric oxide; NONOates; Prodrugs
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test